Prevalence and impact of pain in diabetic neuropathy
DOI:
https://doi.org/10.1002/edn.136Keywords:
Diabetic neuropathy, pain severity, pain interference, anxiety, depressionAbstract
AbstractBackground: Diabetic neuropathy (DNP) is a serious and common complication of diabetes mellitus, with a prevalence of around 30–50%.
Aims: To describe the prevalence, severity and medical treatment of painful DNP (PDNP) experienced by patients treated in secondary care; to determine quality of life (QoL) impact and the relationship between severity of pain and severity of DNP.
Methods: Cross-sectional, two-phase survey. First, a pain interview was conducted by telephone (219 DNP patients), which covered types of pain, location and duration. Secondly, 50 patients were visited at home. Patients completed the Brief Pain Inventory, the Short Form Health Survey (SF–36) and the Hospital Anxiety and Depression Scale.
Results: Prevalence of PDNP was 57.5%. Average and worst pain scores were 5.3±2.1 and 6.4±2.2, respectively (0–10 scale, 10 = worst pain imaginable). In 70% of patients, average pain was severe (score ≥5). Substantial interference by pain (score ≥4) was found in walking ability, sleep and normal activities. PDNP patients had a decreased QoL for all SF–36 domains (p≤0.01) except for health change. Moreover, symptoms of anxiety (36%) and depression (34%) were reported frequently. Medical treatment was prescribed in 46% of patients, in whom treatment was ineffective in 39%. Physical functioning scores were lower in patients with severe versus moderate DNP (p≤0.01).
Conclusions: The prevalence of severe PDNP was high. Severity of DNP was not related to pain severity. PDNP was associated with loss of QoL and with symptoms of anxiety and depression. A considerable proportion of patients did not have medical treatment and, if treatment was given, its impact was disappointing. Medical treatment of PDNP was unsatisfactory and clearly needs to be improved.
Downloads
References
Jude E, Boulton AJM. End stage complications of diabetic neuropathy. Diab Rev 1999; 7: 395–410.
Jude EB, Schaper NC. Treating painful diabetic polyneuropathy. BMJ2007; 335: 57–58.
Meyer-Rosberg K, Kvarnstrom A, Kinnman E , et al. Peripheral neuro-pathic pain: a multidimensional burden for patients. Eur J Pain 2001; 5: 379–389.
Chan AW, MacFarlane IA, Bowsher DR, et al. Chronic pain in patients with diabetes mellitus: comparison with non-diabetic population. The Pain Clinic 1990; 3: 147–159.
Ziegler D, Gries AF, Spuler M, et al. The epidemiology of diabetic neuropathy. J Diabetes Complicat 1992; 6: 49–57.
Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled compari-son of people with and without dia-betes. Diabet Med 2004; 21: 976–982.
Benbow SJ, Wallymahmed ME, MacFarlane A, Diabetic peripheral neuropathy and quality of life. QJ Med 1998; 91: 733–737.
Galer BS, Gianas A, Jensen MP, Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47: 123–128.
Low P, Dotson R. Symptom treat-ment of painful neuropathy. JAMA 1998; 280: 1863–1864.
Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, toler-ability, and impact on quality of life of the 5% lidocaine patch in dia-betic polyneuropathy. Arch Neurol 2004; 61: 914–918.
Polydefkis M, Hauer P, Sheth S, et al. The time course of epidermal nerve fibre regeneration: studies in nor-mal controls and in people with dia-betes, with and without neuropathy. Brain 2004; 127: 1606–1615.
Valk GD, de Sonaville B, van Houtum WH, et al. The assessment of diabetic polyneuropathy in daily clinical practice: reproducibility and validity of Semmes Weinstein monofilaments examination and clinical neurological examination. Muscle Nerve 1997; 20: 116–118.
Zelman DC, Gore M, Dukes E, et al. Validation of a modified version of the Brief Pain Inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage 2005; 29: 401–410.
Keller S, Bann CM, Dodd SL, et al. Validity of the Brief Pain Inventory for use in documenting the out-comes of patients with noncancer pain. Clin J Pain 2004; 20: 309–318.
Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mecha-nisms and treatment recommenda-tions. Arch Neurol 2003; 60: 1524–1534.
Dworkin R, Nagasako E, Galer B. Assessment of neuropathic pain. Handbook of Pain Assessment. New York: Guilford Press, 2002; 519–548.
Health Science Program RAND 36-item Health Survey i.o. Santa Monica, CA: RAND, 1992. www.rand.org/pubs/reprints/RP247/ [accessed 17 July 2009].
Clouet F, Excler-Cavailher G, Christophe B, et al. Type 2 diabetes and short form 36-items health sur-vey. Diabetes Metab 2001; 27: 711–717.
van der Zee KI, Sanderman R. Het meten van de algemene gezondheidstoes-tand met de RAND-36: een handleid-ing. Groningen: Noordelijk Centrum voor Gezondheidsvraagstukken, 1993; 9–14 (in Dutch).
Bjelland I, Dahl A, Haug T, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52: 69–77.
Johnston M, Pollard B, Hennessey P, Construct validation of the Hospital Anxiety and Depression Scale with clinical populations. J Psychosom Res 2000; 48: 579–584.
Spinhoven P, Ormel J, Sloekers P, et al. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychological Med 1997; 27: 363–370.
Croon EM de, Nieuwenhuijsen K, Hugenholtz NIR, et al. Drie vragen-lijsten voor diagnostiek van depressie en angststoornissen. TBV 2005; 13: 98–103 (in Dutch).
Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspec-tives. J Pain 2006; 7: 892–900.
Toelle T, Xu X, Sadosky AB, Painful diabetic neuropathy: a cross-sectional survey of health state impair-ment and treatment patterns. J Diabetes Compli cat 2006; 20: 26–33.
Wit R de, Dam F van, Loonstraa S, et al. The Amsterdam Pain Manage-ment Index compared to eight fre-quently used outcome measures to evaluate the adequacy of pain treat-ment in cancer patients with chronic pain. Pain 2001; 91: 339–349.
Gore M, Brandenburg N, Dukes E, et al. Pain severity in diabetic periph-eral neuropathy is associated with patient functioning, symptom levels of anxiety and depression and sleep. J Pain Symptom Manage 2005; 30: 374–385.
Currie CJ, Poole CD, Woehl A, et al. The health-related utility and health-related quality of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006; 49: 2272–2280.
Vileikyte L, Leventhal H, Gonzalez JS, et al. Diabetic peripheral neuro-pathy and depressive symptoms: the association revisited. Diabetes Care 2005; 28: 2378–2383.
Andreassen CS, Jakobsen J, Andersen H, Muscle weakness: a progressive late complication in dia-betic distal symmetric polyneuro-pathy. Diabetes 2006; 55: 806–812.
Jensen TS, Backonja MM, Hernandez Jimenez, S, et al. New perspectives on the management of diabetic peripheral neuropathic pain. Diabetes Vasc Dis Res 2006; 3: 108–119.
Sorensen L, Molyneaux L, Yue DK, The relationship among pain, sen-sory loss, and small nerve fibers in diabetes. Diabetes Care 2006; 29: 883–887.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2009 Copyright © 2009 FEND
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
